Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agents: Non-psychoactive cannabinoids, 'entourage' compounds and inhibitors of N-acyl ethanolamine breakdown as therapeutic strategies to avoid pyschotropic effects

Brain Research Reviews

Volumn 41, Issue 1, 2003, Pages 26-43

  Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

2 Arachidonoylglycerol; Anandamide; Cannabinoid; Fatty acid amidohydrolase; Ischemia; N Acyl ethanolamine; Neuroprotection

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR; CHEMICAL COMPOUND; DRUG; ETHANOLAMINE DERIVATIVE; N ACYLETHANOLAMINE; N METHYL DEXTRO ASPARTIC ACID; NEUROPROTECTIVE AGENT; PLANT EXTRACT; PSYCHOTROPIC AGENT; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

BRAIN ISCHEMIA; DRUG EFFECT; DRUG INHIBITION; INFLAMMATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; CANNABINOIDS; CEREBROVASCULAR ACCIDENT; ETHANOLAMINES; HUMANS; NEUROPROTECTIVE AGENTS; PLANT EXTRACTS; PSYCHOTROPIC DRUGS; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0037219107     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(02)00218-7     Document Type: Review

References (229)

1. 1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci. Lett. 309:2001;197-2001.
2. Achiron A., Miron S., Lavie V., Margalit R., Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. 102:2000;26-31.
3. 9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study. Eur. J. Pharmacol. 419:2001;155-161.
4. Adam-Klages S., Adam D., Wiegmann K., Struve S., Kolanus W., Schneider-Mergener J., Krönke M. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell. 86:1996;937-947.
5. Andersson M., Jacobsson S.O.P., Jonsson K.-O., Tiger G., Fowler C.J. Neurotoxicity of glutamate in chick telencephalon neurons: reduction of toxicity by preincubation with carbachol, but not by the endogenous fatty acid amides anandamide and palmitoylethanolamide. Arch. Toxicol. 74:2000;161-164.
6. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
7. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
8. Barone F.C., Feuerstein G.Z. Inflammatory mediators and stroke: new opportunities for novel therapies. J. Cereb. Blood Flow Metab. 19:1999;819-834.
9. Beaulieu P., Bisogno T., Punwar S., Farquhar-Smith W.P., Ambrosino G., Di Marzo V., Rice A.S.C. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur. J. Pharmacol. 396:2000;85-92.
10. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.-H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353:1998;23-31.
11. Berdyshev E.V. Inhibition of sea urchin fertilization by fatty acid ethanolamides and cannabinoids. Comp. Biochem. Physiol. C. 122:1999;327-330.
12. Berdyshev E.V. Cannabinoid receptors and the regulation of the immune response. Chem. Phys. Lipids. 108:2000;169-190.
13. + cells. Biochem. J. 346:2000;369-374.
14. Berdyshev E.V., Schmid P.C., Krebsbach R.J., Schmid H.H.O. Activation of PAF receptors results in enhanced synthesis of 2-arachidonoylglycerol (2-AG) in immune cells. FASEB J. 15:2001;2171-2178.
15. Berdyshev E., Biochot E., Corbel M., Germain N., Lagente V. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci. 63:1998;PL125-PL129.
16. Berdyshev E.V., Schmid P.C., Krebsbach R.J., Hillard C.J., Huang C., Chen N., Dong Z., Schmid H.H.O. Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. Biochem. J. 360:2001;67-75.
17. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272:1997;3315-3323.
18. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322:1997;671-677.
19. Bisogno T., Hanus L., De Petrocellis L., Tchilibon S., Ponde D.E., Brandi I., Moriello A.S., Davis J.B., Mechoulam R., Di Marzo V. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134:2001;845-852.
20. Blázquez C., Sanchéz C., Daza A., Galve-Roperh I., Guzmán M. The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme. J. Neurochem. 72:1999;1759-1768.
21. Blomqvist P., Lindvall O., Stenevi U., Wieloch T. Cyclic AMP concentrations in rat neocortex and hippocampus during and following incomplete ischemia: effects of central noradrenergic neurons, prostaglandins, and adenosine. J. Neurochem. 44:1985;1345-1353.
22. Boger D.L., Fecik R.A., Patterson J.E., Miyauchi H., Patricelli M.P., Cravatt B.F. Fatty acid amide hydrolase substrate specificity. Bioorg. Med. Chem. Lett. 10:2000;2613-2616.
23. i-mediated mitogen activated protein kinase signaling transduction pathways. FEBS Lett. 449:1999;61-65.
24. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272:1997;22330-22339.
25. Breivogel C.S., Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Disease. 5:1998;417-431.
26. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol. 60:2001;155-163.
27. Bueb J.L., Lambert D.M., Tschirhart E.J. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim. Biophys. Acta. 1538:2001;252-259.
28. 1 receptor-deficient mice. Hypertension. 39:2002;251-257.
29. 9tetrahydrocannabinol. Proc. Soc. Exp. Biol. Med. 210:1995;64-76.
30. Burstein S.H. The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharm. Ther. 82:1999;87-96.
31. Burstein S.H. Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr. Pharmaceut. Des. 6:2000;1339-1345.
32. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:1996;3934-3942.
33. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
34. Calignano A., La Rana G., Piomelli D. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur. J. Pharmacol. 419:2001;191-198.
35. Campbell V.A. Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation. Neuropharmacology. 40:2001;702-709.
36. Capasso R., Izzo A.A., Fezza F., Pinto A., Capasso F., Mascolo N., Di Marzo V. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br. J. Pharmacol. 134:2001;945-950.
37. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
38. 9-tetrahydrocannabinol. J. Neurosci. 18:1998;5322-5332.
39. Chang Y.H., Lin S.T., Lin W.W. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J. Cell. Biochem. 81:2001;716-723.
40. 2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology. 38:1999;533-541.
41. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20:2001;7033-7040.
42. Chen Y., McCarron R.M., Ohara Y., Bembry J., Azzam N., Lenz F.A., Shohami E., Mechoulam R., Spatz M. Human brain capillary endothelium 2-arachidonoylglycerol (endocannabinoid) interacts with endothelin-1. Circ. Res. 87:2000;323-327.
43. Cheung H.H., Teves L., Wallace M.C., Gurd J.W. Increased phosphorylation of the NR1 subunit of the NMDA receptor following cerebral ischemia. J. Neurochem. 78:2001;1179-1182.
44. 4 muscarinic acetylcholine receptors. Brain Res. 915:2001;70-78.
45. Cocchiara R., Bongiovanni A., Albeggiani G., Azzolina A., Geraci D. Evidence that brain mast cells can modulate neuroinflammatory responses by tumour necrosis factor-α production. NeuroReport. 9:1998;95-98.
46. Coffey R.G., Snella E., Johnson K., Pross S. Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. Int. J. Immunopharmacol. 18:1996;749-752.
47. Coffey R.G., Yamamoto Y., Snella E., Pross S. Tetrahydrocannabinol inhibition of macrophage nitric oxide production. Biochem. Pharmacol. 52:1996;743-751.
48. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur. Neurol. 38:1997;44-48.
49. Conti S., Costa B., Colleoni M., Parolaro D., Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol. 135:2002;181-187.
50. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
51. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA. 98:2001;9371-9376.
52. Czyborra P., Saxe M., Fetscher C., Meyer zu Heringdorf D., Herzig S., Jakobs K.H., Michel M.C., Bischoff A. Transient relaxation of rat mesenteric microvessels by ceramides. Br. J. Pharmacol. 135:2002;417-426.
53. Dardzinski B.J., Smith S.L., Towfighi J., Williams G.D., Vannucci R.C., Smith M.B. Increased plasma beta-hydroxybutyrate, preserved cerebral energy metabolism, and amelioration of brain damage during neonatal hypoxia ischemia with dexamethasone pretreatment. Pediatr. Res. 48:2000;248-255.
54. 1 receptor antagonist SR 141716A in naive mice. J. Neural Transm. 107:2000;931-945.
55. Day T.A., Rakhshan F., Deutsch D.G., Barker E.L. Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. 59:2001;1369-1375.
56. A Deadwyler S., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels. 1:1993;121-134.
57. De Petrocellis L., Davis J.B., Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 506:2001;253-256.
58. De Petrocellis L., Orlando P., Di Marzo V. Anandamide, an endogenous cannabinomimetic substance, modulates rat brain protein kinase C in vitro. Biochem. Mol. Biol. Intl. 36:1995;1127-1133.
59. De Petrocellis L., Bisogno T., Maccarone M., Davis J.B., Finazzi-Agrò A., Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276:2001;12856-12863.
60. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
61. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., Abumrad N. The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase (FAAH). J. Biol. Chem. 276:2001;6967-6973.
62. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
63. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392:1998;153-175.
64. Di Marzo V., Bisogno T., De Petrocellis L. Anandamide: some like it hot. Trends Pharmacol. Sci. 22:2001;346-349.
65. Di Marzo V., De Petrocellis L., Bisogno T., Melck D. Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids. 34:1999;S319-S325.
66. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264:1999;258-267.
67. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
68. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagory O., Bifulco M., Vogel Z., De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358:2001;249-255.
69. Dinh T.P., Carpenter D., Leslie F.M., Freund T., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocanabinoid inactivation. Proc. Natl. Acad. Sci. USA. 99:2002;10819-10824.
70. Dirnagl U., Iadecola C., Moskowitz M.A. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci. 22:1999;391-397.
71. 2+ release from mitochondria by N-acylethanolamines, a class of lipids synthesized in ischemic heart tissue. J. Biol. Chem. 257:1982;1383-1391.
72. Epps D.E., Schmid P.C., Natarajan V., Schmid H.H.O. N-Acylethanolamine accumulation in infarcted myocardium. Biochem. Biophys. Res. Commun. 90:1979;628-633.
73. Eshhar N., Striem S., Kohen R., Tirosh O., Biegon A. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist. Eur. J. Pharmacol. 283:1995;19-29.
74. Esposito G., Izzo A.A., Di Rosa M., Iuvone T. Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. J. Neurochem. 78:2001;835-841.
75. Esposito P., Gheorghe D., Kandere K., Pang X., Connolly R., Jacobson S., Theohorides T.C. Acute stress increases permeability of the blood-brain barrier through activation of brain mast cells. Brain Res. 888:2001;117-127.
76. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripherial cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
77. Farquhar-Smith W.P., Rice A.S.C. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 94:2001;507-513.
78. Farquhar-Smith W.P., Rice A.S.C. The effect of endocannabinoids on peripheral NGF-induced neutrophil accumulation in rat skin. Symposium on the Cannabinoids, Vermont, International Cannabinoid Research Society, 2001;76.
79. Fezza F., Bisogno T., Minassi A., Appendino G., Mechoulam R., Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513:2002;294-298.
80. Fowler C.J., Börjesson M., Tiger G. Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br. J. Pharmacol. 131:2000;498-504.
81. Fowler C.J., Jonsson K.-O., Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide and oleamide. Biochem. Pharmacol. 62:2001;517-526.
82. 2 receptor-like immunoreactivity in the embryonic chick brain. Pharmacol. Toxicol. 88:2001;213-222.
83. Gallily R., Breuer A., Mechoulam R. 2-Arachidonoylglycerol, an endogenous cannabinoid, inhibits tumour necrosis-α production in murine macrophages, and in mice. Eur. J. Pharmacol. 406:2000;R5-R7.
84. Galve-Roperh I., Sánchez C., Cortés M.L., Gómez del Pulgar T., Izquierdo M., Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Med. 6:2000;313-319.
85. Garcia D.E., Brown S., Hille B., Mackie K. Protein kinase C disrupts cannabinoid actions by phosphorylation of the CB1 cannabinoid receptor. J. Neurosci. 18:1998;2834-2841.
86. Gauldie S.D., McQueen D.S., Pertwee R., Chessell I.P. Anandamide activates peripheral nociceptors in normal and arthritic knee joints. Br. J. Pharmacol. 132:2001;617-621.
87. Gifford A.N., Bruneus M., Gatley S.J., Lan R., Makriyannis A., Volkow N.D. Large receptor reserve for cannabinoid actions in the central nervous system. J. Pharmacol. Exp. Ther. 288:1999;478-483.
88. Goparaju S.K., Ueda N., Taniguchi K., Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem. Pharmacol. 57:1999;417-423.
89. Granberg M., Fowler C.J., Jacobsson S.O.P. Effects of the cannabimimetic fatty acid derivatives 2-arachidonoylglycerol, anandamide, palmitoylethanolamide and methanandamide upon IgE-dependent antigen-induced β-hexosaminidase, serotonin and TNFα release from rat RBL-2H3 basophilic leukaemic cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 364:2001;66-73.
90. 2 receptor absence in the rat central nervous system. Eur. J. Pharmacol. 377:1999;117-125.
91. Grundy R.I., Rabuffetti M., Beltramo M. Cannabinoids and neuroprotection. Mol. Neurobiol. 24:2001;29-51.
92. Gulaya N.M., Kuzmenko A.I., Margitich V.M., Govseeva N.M., Melnichuk S.D., Goridko T.M., Zhukov A.D. Long-chain N-acylethanolamines inhibit lipid peroxidation in rat liver mitochondria under acute hypoxic hypoxia. Chem. Phys. Lipids. 97:1998;49-54.
93. Guzmán M., Galve-Roperh I., Sánchez C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci. 22:2001;19-22.
94. Haimovitz-Friedman A., Kolesnick R.N., Fuks Z. Ceramide signaling in apoptosis. Br. Med. Bull. 53:1997;539-553.
95. Hájos N., Ledent C., Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 106:2001;1-4.
96. Hampson A.J., Grimaldi M. Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity. Eur. J. Neurosci. 13:2001;1529-1536.
97. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA. 95:1998;8268-8273.
98. Hampson A.J., Bornheim L.M., Scanziani M., Yost C.S., Gray A.T., Hansen B.M., Lenoudakis D.L., Bickler P.E. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J. Neurochem. 70:1998;671-676.
99. s proteins in cultured hippocampal neurons. J. Neurophysiol. 84:2000;2356-2364.
100. Hunnun Y.A., Luberto C. Ceramide in the eukaryotic stress response. Trends Cell. Biol. 10:2000;73-80.
101. Hansen H.H., Hansen S.H., Schousboe A., Hansen H.S. Determination of the phospholipid precursor of anandamide and other N-acylethanolamine phospholipids before and after sodium azide-induced toxicity in cultured neocortical neurons. J. Neurochem. 75:2000;861-871.
102. Hansen H.H., Ikonomidou C., Bittigau P., Hansen S.H., Hansen H.S. Accumulation of the anandamide precursor and other N-acylethanolamine phospholipids in infant rat models of in vivo necrotic and apoptotic neuronal death. J. Neurochem. 76:2001;39-46.
103. Hansen H.H., Schmid P.C., Bittigau P., Lastres-Becker I., Berrendero F., Manzanares J., Ikonomidou C., Schmid H.H.O., Fernández-Ruiz J.J., Hansen H.S. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. 78:2001;1415-1427.
104. Hansen H.S., Lauritzen L., Moesgaard B., Strand A.M., Hansen H.H. Formation of N-acyl-phosphatidylethanolamines and N-acylethanolamines. Proposed role in neurotoxicity. Biochem. Pharmacol. 55:1998;719-725.
105. Hansen H.S., Lauritzen L., Strand A.M., Moesgaard B., Frandsen A. Glutamate stimulates the formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cortical neurons in culture. Biochim. Biophys. Acta. 1258:1995;303-308.
106. Hansen H.S., Lauritzen L., Strand A.M., Vinggaard A.M., Frandsen A., Schousboe A. Characterization of glutamate-induced formation of N-acylphosphatidylethanolamine and N-acylethanolamine in cultured neocortical neurons. J. Neurochem. 69:1997;753-761.
107. Hansen H.S., Moesgaard B., Hansen H.H., Petersen G. N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem. Phys. Lipids. 108:2000;135-150.
108. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
109. 1 receptor. Proc. Natl. Acad. Sci. USA. 98:2001;3662-3665.
110. Herkenham M., Lynn A.B., Little M.D., Johnson R.M., Melvin L.S., De Costa B.R., Rice K.C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
111. Hillard C.J. Endocannabinoids and vascular function. J. Pharmacol. Exp. Ther. 294:2000;27-32.
112. 1 cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett. 459:1999;277-281.
113. Hillard C.J., Edgemond W.S., Jarrahian A., Campbell W.B. Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. 69:1997;631-638.
114. Howlett A.C. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol. Pharmacol. 27:1985;429-436.
115. Huang C.-C., Lo S.-W., Hsu K.-S. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J. Physiol. 532:2001;731-748.
116. Huang C.-C., Chen Y.-L., Lo S.-W., Hsu K.-S. Activation of cAMP-dependent protein kinase suppresses the presynaptic cannabinoid inhibition of glutamatergic transmission at corticostriatal synapses. Mol. Pharmacol. 61:2002;578-585.
117. Huang S.M., Bisogno T., Petros T.J., Chang S.Y., Zavitsanos P.A., Zipkin R.E., Sivakumar R., Coop A., Maeda D.Y., De Petrocellis L., Burstein S., Di Marzo V., Walker J.M. Identification of a new class of molecules, the arachidonoyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem. 276:2001;42639-42644.
118. Huestis M.A., Gorelick D.A., Heishman S.J., Preston K.L., Nelson R.A., Moolchan E.T., Frank R.A. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Arch. Gen. Psychiatry. 58:2001;322-328.
119. Jacobsson S.O.P., Fowler C.J. Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br. J. Pharmacol. 132:2001;1743-1754.
120. Jacobsson S.O.P., Wallin T., Fowler C.J. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299:2001;951-959.
121. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S.C. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
122. Jeon Y.J., Yang K.H., Pulaski J.T., Kaminski N.E. Attenuation of inducible nitric oxide synthase gene expression by delta 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-kappa B/Rel activation. Mol. Pharmacol. 50:1996;334-341.
123. Jin K.L., Mao X.O., Goldsmith P.C., Greenberg D.A. CB1 cannabinoid receptor induction in experimental stroke. Ann. Neurol. 48:2000;257-261.
124. Jonsson K.-O., Vandevoorde S., Lambert D.M., Tiger G., Fowler C.J. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br. J. Pharmacol. 133:2001;1263-1275.
125. Kahlich R., Klina J., Cihla F., Frankova V., Masek K., Rosicky M., Matousek F., Bruthans J. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J. Hyg. Epidemiol. Microbiol. Immunol. 23:1979;11-24.
126. 1 receptor-deficient mice. Br. J. Pharmacol. 132:2001;1169-1173.
127. Kim D., Thayer S.A. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J. Neurosci. 21:2001;RC146.
128. Klein T.W., Newton C., Friedman H. Cannabinoid receptors and immunity. Immunol. Today. 19:1998;373-381.
129. Kondo S., Sugiura T., Kodaka T., Kudo N., Waku K., Tokumura A. Accumulation of various N-acylethanolamines including N-arachidonoylethanolamine (anandamide) in cadmium chloride-administered rat testis. Arch. Biochem. Biophys. 354:1998;303-310.
130. Kouznetsova M., Kelley B., Shen M., Thayer S.A. Desensitization of cannabinoid-mediated presynaptic inhibition of neurotransmission between rat hippocampal neurons in culture. Mol. Pharmacol. 61:2002;477-485.
131. Kunos G., Járai Z., Varga K., Liu J., Wang L., Wagner J.A. Cardiovascular effects of endocannabinoids - the plot thickens. Prostaglandins Other Lipid Med. 61:2000;71-84.
132. Lambert D.M., Vandevoorde S., Jonsson K.-O., Fowler C.J. The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr. Med. Chem. 9:2002;663-674.
133. Lambert D.M., Vandevoorde S., Diependaele G., Govaerts S., Robert A.R. Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice. Epilepsia. 42:2001;321-327.
134. 2 cannabinoid, as potential ligands for the cannabinoid receptor. Biochim. Biophys. Acta. 1440:1999;266-274.
135. 1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
136. Lavie G., Teichner A., Shohami E., Ovadia H., Leker R.R. Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia. Brain Res. 901:2001;195-201.
137. Lévénès C., Daniel H., Soubrié P., Crépel F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J. Physiol. 510:1998;867-879.
138. Louw D.F., Yang F.W., Sutherland G.R. The effect of δ-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. 857:2000;183-187.
139. Maccarrone M., Fiorucci L., Erba F., Bari M., Finazzi-Agrò A., Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett. 468:2000;176-180.
140. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agró A. Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275:2000;31938-31945.
141. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
142. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium current as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
143. Mailleux P., Vanderhaeghen J.-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
144. + channel TASK-1. EMBO J. 20:2001;47-54.
145. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., Feldmann M. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 97:2000;9561-9566.
146. Malinski T., Bailey F., Zhang Z.G., Chopp M. Nitric oxide measured by a porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 13:1993;355-358.
147. Marsicano G., Moosmann B., Hermann H., Lutz B., Behl C. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. 80:2002;448-456.
148. Martin B.R., Beletskaya I., Patrick G., Jefferson R., Winckler R., Deutsch D.G., Di Marzo V., Dasse O., Mahadevan A., Razdan R.K. Cannabinoid properties of methylfluorophosphonate analogues. J. Pharmacol. Exp. Ther. 294:2000;1209-1218.
149. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
150. Maurelli S., Bisogno T., De Petrocellis L., Luccia A.D., Marino G., Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett. 377:1995;82-86.
151. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl) hexadecamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell. Eur. J. Pharmacol. 300:1996;227-236.
152. Mechoulam R., Panikashvili D., Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol. Med. 8:2002;58-61.
153. 1 cannabinoid receptor. Biochem. Pharmacol. 60:2000;1315-1323.
154. Moesgaard B., Jaroszewski J.W., Hansen H.S. Accumulation of N-acyl-ethanolamine phospholipids in rat brains during post-decapitative
155. Moesgaard B., Peternsen G., Mortensen S.A., Hansen H.S. Substantial species differences in relation to formation and degradation of N-acyl-ethanolamine phospholipids in heart tissue: an enzyme activity study. Comp. Biochem. Physiol. B. 131:2002;475-482.
156. 31P NMR and enzyme activity study. J. Lipid Res. 41:2000;985-990.
157. Molina-Holgado F., Lledó A., Guaza C. Anandamide suppresses nitric oxide and TNF-α responses to Theiler's virus or endotoxin in astrocytes. NeuroReport. 8:1997;1929-1933.
158. 2 receptors in the inhibitory effects of cannabinoids on the lipopolysaccharide-induced nitric oxide release in astrocyte cultures. J. Neurosci. Res. 67:2002;829-836.
159. Mrsulja B.B., Djuricic B.M., Kostic V.S., Panic M. Cyclic AMP in the cerebrospinal fluid of patients with recent cerebral infarction. Eur. Neurol. 23:1984;201-205.
160. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., Greenburg D.A. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. 19:1999;2987-2995.
161. Natarajan V., Schmid P.C., Schmid H.H.O. N-Acylethanolamine phospholipid metabolism in normal and ischemic rat brain. Biochim. Biophys. Acta. 878:1986;32-41.
162. 2+ signals in cerebellar granule neurons in culture. J. Neurosci. 19:1999;8765-8777.
163. Nie J., Lewis D.L. Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration. J. Neurosci. 21:2001;8758-8764.
164. Nogueron M.I., Porgilsson B., Schneider W.E., Stucky C.L., Hillard C.J. Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons. J. Neurochem. 79:2001;371-381.
165. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729-738.
166. Pahan K., Namboodiri A.M.S., Sheikh F.G., Smith B.T., Singh I. Increasing cAMP attenuates induction of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem. 272:1997;7786-7791.
167. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
168. Pang X., Letorneau R., Rozniecki J.J., Wang L., Theoharides T.C. Definitive characterization of rat hypothalamic mast cells. Neuroscience. 73:1996;899-902.
169. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature. 413:2001;527-531.
170. Parinandi N.L., Schmid H.H.O. Effects of long-chain N-acylethanolamines on lipid peroxidation in cardiac mitochondria. FEBS Lett. 237:1988;49-52.
171. Parmentier-Batteur S., Bohme G.A., Lerouet D., Zhou-Ding L., Beray V., Margaill I., Plotkine M. Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury. J. Cereb. Blood Flow Metab. 21:2001;15-21.
172. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Exp. Opin. Invest. Drugs. 9:2000;1553-1571.
173. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63:2001;569-611.
174. Ponti W., Rubino T., Bardotti M., Poli G., Parolaro D. Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages. Vet. Immunol. Immunopathol. 82:2001;203-214.
175. Prevot V., Rialas C.M., Croix D., Salzet M., Dupouy J.-P., Poulain P., Beauvillain J.-C., Stefano G.B. Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Res. 790:1998;236-244.
176. Rice A.S.C. Cannabinoids and pain. Curr. Opin. Invest. Drugs. 2:2001;399-414.
177. Ridet J.L., Malhotra S.K., Privat A., Gage F.H. Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. 20:1997;570-577.
178. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., Ferrera P., Soubrié P., Brelière J.-C., le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
179. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Brelière J.-C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
180. Rodríguez de Fonseca F., Navarro M., Gómez R., Escuredo L., Nava F., Fu J., Murillo-Rodríguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., Piomelli D. An anorexic lipid mediator regulated by feeding. Nature. 414:2001;209-212.
181. Ross R.A., Brockie H.C., Pertwee R.G. Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide. Eur. J. Pharmacol. 401:2000;121-130.
182. Sagan S., Venance L., Torrens Y., Cordier J., Glowinski J., Giaume C. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur. J. Neurosci. 11:1999;691-699.
183. 9-tetrahydrocanabinol induces apoptosis in C6 glioma cells. FEBS Lett. 436:1998;6-10.
184. 9-tetrahydrocanabinol-induced stimulation of glucose metabolism in primary astrocytes. Mol. Pharmacol. 54:1998;834-843.
185. 1 cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol. Pharmacol. 59:2001;955-959.
186. 1 receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 134:2001;664-672.
187. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22:2001;565-572.
188. Schmid H.H.O. Pathways and mechanisms of N-acylethanolamine biosynthesis: can anandamide be generated selectively? Chem. Phys. Lipids. 108:2000;71-87.
189. Schmid H.H.O., Schmid P.C., Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 29:1990;1-43.
190. Schmid P.C., Zuzarte-Augustin M.L., Schmid H.H.O. Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 260:1985;14145-14149.
191. Science and Technology Committee of the House of Lords, 9th Report, 11 November 1998. Cannabis: The Scientific and Medical Evidence. published online at http://www.parliament.the-stationery-office.co.uk/pa/ld199798/ldselect/ ldsctech/151/15101.htm.
192. Shen M., Thayer S.A. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. 54:1998;459-462.
193. Shen M., Piser T.M., Seybold V.S., Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16:1996;4322-4334.
194. Sheskin T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
195. Shimizu-Sasamata M., Bosque-Hamilton P., Huang P.L., Moskowitz M.A., Lo E.H. Attenuated neurotransmitter release and spreading depression-like depolarizations after focal ischemia in mutant mice with disrupted type I nitric oxide synthase gene. J. Neurosci. 18:1998;9564-9571.
196. Shohami E., Gallily R., Mechoulam R., Bass R., Ben-Hur T. Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-α inhibitor and an effective neuroprotectant. J. Neuroimmunol. 72:1997;169-177.
197. Sim-Selley L., Brunk L.K., Selley D.E. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 414:2001;135-143.
198. Sinor A.D., Irvin S.M., Greenberg D.A. Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. 278:2000;157-160.
199. Skaper S.D., Facci L., Romanello S., Leon A. Mast cell activation causes delayed neurodegeneration in mixed hippocampal cultures via the nitric oxide pathway. J. Neurochem. 66:1996;1157-1166.
200. Skaper S.D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA. 93:1996;3984-3989.
201. Smart D., Jonsson K.-O., Vandevoorde S., Lambert D.M., Fowler C.J. 'Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 136:2002;452-458.
202. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
203. Stefano G.B., Liu Y., Goligorsky M.S. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J. Biol. Chem. 271:1996;19238-19242.
204. Stefano G.B., Rialas C.M., Deutsch D.G., Salzet M. Anandamide amidase inhibition enhances anandamide-stimulated nitric oxide release in invertebrate neural tissues. Brain Res. 793:1998;341-345.
205. Stella N., Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425:2001;189-196.
206. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
207. Strelow A., Bernardo K., Adam-Klages S., Linke T., Sandhoff K., Krönke M., Adam D. Overexpression of acid ceramidase protects from tumor necrosis factor-induced death. J. Exp. Med. 192:2000;601-611.
208. Sugita M., Williams M., Dulaney J.T., Moser H.W. Ceramidase and ceramide synthesis in human kidney and cerebellum. Description of a new alkaline ceramidase. Biochim. Biophys. Acta. 398:1975;125-131.
209. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues and related compounds. J. Biol. Chem. 274:1999;2794-2801.
210. Sugiura T., Kondo S., Sugukawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
211. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50.
212. Ueda N., Yamanaka K., Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J. Biol. Chem. 276:2001;35552-35557.
213. 9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J. Neurosci. 21:2001;6475-6479.
214. van der Stelt M., Veldhuis W.B., van Haaften G.W., Fezza F., Bisogno T., Bär P.R., Veldink G.A., Vliegenthart J.F.K., Di Marzo V., Nicolay K. Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. 21:2001;8765-8771.
215. Vandevoorde S., Lambert D.M. Effects of the cannabinoids WIN55212-2 and WIN55212-3 on lipopolysaccharide stimulated nitric oxide production in murine macrophages. Symposium on the Cannabinoids, Vermont, International Cannabinoid Research Society, 2001;149.
216. Varma N., Carlson G.C., Ledent C., Alger B.E. Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus. J. Neurosci. 21:2001;RC188.
217. Vásquez C., Lewis D.L. The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J. Neurosci. 19:1999;9271-9280.
218. Wagner J.A., Varga K., Ellis E.F., Rzigalinski B.A., Martin B.R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
219. Wagner J.A., Hu K., Bauersachs J., Karcher J., Wiesler M., Goparaju S.K., Kunos G., Ertl G. Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J. Am. Coll. Cardiol. 38:2001;2048-2054.
220. Waksman Y., Olson J.M., Carlisle S.J., Chabral G.A. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J. Pharmacol. Exp. Ther. 288:1999;1357-1366.
221. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sañudo-Peña M. Pain modulation by release of the endogenous cannabinoid anandamide. Proc. Natl. Acad. Sci. USA. 96:1999;12198-12203.
222. Watanabe K., Matsunaga T., Nakamura S., Kimura T., Ho I.K., Yoshimura H., Yamamoto I. Pharmacological effects in mice of anandamide and its related fatty acid ethanolamides, and enhancement of cataleptogenic effect of anandamide by phenylmethylsulfonyl fluoride. Biol. Pharm. Bull. 22:1999;366-370.
223. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592.
224. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science. 296:2002;678-682.
225. Yoshida T., Hashimoto K., Zimmer A., Maejima T., Araishi K., Kano M. The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J. Neurosci. 22:2002;1690-1697.
226. Zablocka B., Gajkowska B., Czechmanska T., Domansla-Janik K. Isoforms of protein kinase C in postsynaptic densities after cerebral ischemia. Brain Res. 889:2001;105-111.
227. Zhuang X., Silverman A.J., Silver R. Brain mast cell degranulation regulates blood-brain barrier. J. Neurobiol. 31:1996;393-403.
228. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannnabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780-5785.
229. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H.-H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.